Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 2Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3

Conditions

Lymphoma 200Leukemia 159Leukemia, Myeloid, Acute 134Precursor Cell Lymphoblastic Leukemia-Lymphoma 132Lymphoma, Non-Hodgkin 111Multiple Myeloma 110Lymphoma, Large B-Cell, Diffuse 108Lymphoma, Follicular 93Hodgkin Disease 91Burkitt Lymphoma 91Myelodysplastic Syndromes 87Lymphoma, Mantle-Cell 87Leukemia, Lymphocytic, Chronic, B-Cell 84Breast Neoplasms 84Lymphoma, Large-Cell, Immunoblastic 73Lymphoma, B-Cell, Marginal Zone 59Sarcoma 54Neoplasms, Plasma Cell 50Neuroblastoma 49Central Nervous System Neoplasms 46Leukemia, Myeloid, Chronic-Phase 43Recurrence 40Ovarian Neoplasms 39Leukemia, Myeloid, Accelerated Phase 39Congenital Abnormalities 39Myeloproliferative Disorders 38Dendritic Cell Sarcoma, Interdigitating 38Blast Crisis 34Leukemia, Myelomonocytic, Chronic 32Neutropenia 29

Interventions

Cytarabine 14fludarabine 13venetoclax 11Imatinib Mesylate 9Cyclophosphamide 8Azacitidine 8fludarabine phosphate 7Busulfan 7Whole-Body Irradiation 6Tacrolimus 6Mycophenolic Acid 6thymoglobulin 4ponatinib 4nilotinib 4Sirolimus 4Peripheral Blood Stem Cell Transplantation 4Methotrexate 4asciminib 3aldesleukin 3Melphalan 3Interleukin-2 3Idarubicin 3Granulocyte Colony-Stimulating Factor 3Filgrastim 3Decitabine 3Antilymphocyte Serum 3zosuquidar trihydrochloride 2gilteritinib 2enasidenib 2blinatumomab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Leukemia, Myeloid × Filgrastim × Clear all
NCT07604233 2026-05-22

Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML

M.D. Anderson Cancer Center

Phase 1/2 Not yet recruiting
30 enrolled
Other hematologic neoplasm

Leukemia, Myeloid

NCT00943943 2017-03-29

Granulocyte-colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 Mutations

M.D. Anderson Cancer Center

Phase 1 Completed
33 enrolled
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute

NCT00114764 2008-10-31

Trial Comparing Pegfilgrastim With Filgrastim as an Adjunct to Chemotherapy for Acute Myeloid Leukaemia (AML)

Amgen

Phase 2 Completed
84 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Neutropenia, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡